Navigation Links
CellMax Life to Provide Blood Test for Medigen Biotech’s Colorectal Cancer Cell Therapy Clinical Trials

CellMax Life, a diagnostics company with a proprietary technology to detect precancer and cancer cells in blood, has been named as a partner in Medigen Biotech’s upcoming cell therapy clinical trials. Medigen Biotech, a global biotech company developing cell therapies for cancer treatment, will use CellMax Life’s circulating tumor cell platform CMxTM, in combination with its comprehensive liquid biopsy panel to assess treatment selection and response.

Immune cells are cells in the body's immune system that are responsible for combating foreign pathogens and removing tumors or damaged tissues from the body. Natural killer (NK) cells are the body’s first line of defense against cancer. Medigen Biotech is able to culture NK cells, without the use of genetically modified substances, to effectively increase the number and purity of NK cells, increasing their toxic ability to kill cancer cells.

The planned open-label, multi-center, single arm clinical trial is expected to enroll patients with Stage II and III colorectal cancer that has been surgically resected, or surgically resected and treated with chemotherapy. For the phase I trial, expected to initiate in 2019, patients who test positive on the CellMax Life blood test will receive the NK cell therapy. This trial is designed to monitor patients multiple times during the course of treatment, using the CellMax blood test, to assess treatment response.

CellMax Life's proprietary blood test uniquely isolates and analyzes both circulating tumor cells and circulating tumor DNA from a single sample of blood for the assessment of six types of analytes including four classes of genomic alterations, micro-satellite instability and circulating tumor cells.

"For this clinical trial, we needed a non-invasive blood test that can be used to screen for initial treatment selection, but also used multiple times during the course of treatment to monitor patients," Dr. Stanley Chang, Chairman and CEO of Medigen Biotech said in a statement. "Because we expect to recruit patients with early stage cancer, test sensitivity was the key criteria for platform selection. We were very impressed with the sensitivity of the CellMax Life circulating tumor cell platform CMx for the detection of colorectal cancer presented at ASCO's gastrointestinal symposium. By combining the CMx assay with the CellMax ctDNA based liquid biopsy, which is comparable to the best-in-class ctDNA liquid biopsies in performance, we hope to have the most sensitive test for treatment selection and monitoring response."

"Colorectal cancer is the second deadliest cancer in the U.S., with 150,000 new cases and $14 billon spent on treatment annually,” said Atul Sharan, Co- Founder and CEO of CellMax Life. “Medigen’s vision to develop innovative cancer therapies especially for the earlier stages of cancer when it is most treatable, is very much aligned to CellMax Life’s mission to reduce mortality from colorectal cancer. We are pleased that the coming clinical trial would bring benefits to colorectal cancer patients.”

About CellMax Life
CellMax Life is a diagnostics company focused on cancer screening with a proprietary technology for detecting precancer and cancer cells in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has a CLIA certified and CAP accredited laboratory at this location. For more information, visit

About Medigen Biotech
Medigen Biotech is a biopharmaceutical company focused on novel cell therapy technology and new drug development for cancer treatment. The company has now developed into a biomedical group with business fields also covering molecular diagnosis, cell-based vaccine technology, biologics and ophthalmic drug manufacturing. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Ingenuity Systems IPA Provides Researchers with Genomic Insights Suggesting that Physical Activity Does Not Slow Muscle Aging
3. Simagis Digital Web Pathology Launches Service Provider Network
4. CHI Vice President Provides Testimony On Patient, Physician Notification of Biosimilar Substitution
5. Antimicrobial Test Laboratories Emerges as Leading Provider of Virus Testing Services
6. Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Announces the Highly Anticipated Release of Medrio 8.1 with iPad Support
7. Celsion Corporation Provides Business Update
8. 2013 Bio Convention Provides Springboard For Malaysian Biotech
9. Cellular Biomedicine Group Provides Update and 2013 Milestones
10. Emergent Technologies and Caisson Biotech Form Strategic Alliance with Local Health Care Providers to Improve Delivery and Performance of a Therapeutic Drug
11. Adamis Pharmaceuticals CEO Provides Update for Shareholders
Post Your Comments:
(Date:3/5/2019)... ... March 05, 2019 , ... San Fransisko, or Sisko for short, is ... four years old to pursue a career in dressage. According to Deborah, dressage ... horse that she’d ever worked with. Unfortunately, Sisko suffered an injury while playing ...
(Date:2/27/2019)... ... February 27, 2019 , ... Lajollacooks4u is ... the San Diego-based team-building and cooking events company will be offering a new ... , This fun-filled, interactive team-building event involves pairing two popular items together – ...
(Date:2/22/2019)... ... February 20, 2019 , ... Murrieta Genomics ... in the rapidly growing NGS (Next Generation Sequencing) field, have announced a partnership ... incubator. , "As an innovation center and idea incubator, we are always looking ...
(Date:2/19/2019)... , ... February 19, 2019 , ... VetStem Biopharma ... and manufacturing experience. In October 2018, VetStem authorized the formation of Personalized Stem ... PSC its stem cell patents, data, and FDA filings to launch into human stem ...
Breaking Biology Technology:
(Date:3/9/2019)... ... March 08, 2019 , ... Ace ... product, Well-Mints™ resveratrol + ribose hard candy lozenges ( ). , Well-Mints™ ... naturally flavored hard candy base dusted with powdered sugar. , Well-Mints'™ patented technology ...
(Date:3/5/2019)... ... 05, 2019 , ... Join this live webinar on Thursday, March ... analysts and bioinformaticians focus on data analysis without worrying about data management-related activities. ... source systems. Some sources of data include:, , Clinical Trial ...
(Date:3/1/2019)... SAN DIEGO (PRWEB) , ... February 28, 2019 , ... ... Klinikum Rechts der Isar of the Technical University Munich, has been awarded an xCELLigence ... immunotherapeutic for an improved oncolytic virus platform. , Oncolytic viruses represent an ...
Breaking Biology News(10 mins):